Author:
Zhou Jian-Fu,Zhang Yi-Bing,Zhang Zhi-Wei
Abstract
BackgroundThis study aimed to compare the efficacy of budesonide inhalation suspension administered via a vibrating mesh nebulizer vs. a jet nebulizer in the treatment of premature infants with bronchopulmonary dysplasia (BPD) undergoing high-frequency oscillatory ventilation (HFOV).MethodsBetween July 2020 and July 2022, we retrospectively analyzed the medical records of 36 preterm infants diagnosed with BPD who underwent HFOV. Based on the nebulizer type used, infants were categorized into the vibrating mesh nebulizer group (VMN group) or the jet nebulizer group (JN group). Post-nebulization outcomes, such as the duration of mechanical ventilation, length of stay in the neonatal intensive care unit (NICU), ventilator-associated parameters, and arterial blood gas metrics, were compared between the two groups. Treatment-associated complications were also documented.ResultsNo significant differences were noted between the VMN and JN groups in terms of mechanical ventilation duration (p = 0.519), NICU length of stay (p = 0.112), ventilator-associated parameters, or complications (p = 0.700). However, after 2 weeks of treatment, the oxygenation index (p = 0.012) and arterial partial pressure of carbon dioxide (p = 0.006) were more favorable in the VMN group compared to the JN group.ConclusionAmong premature infants with BPD on HFOV, for administration of budesonide inhalation suspension resulted in an improved oxygenation index and reduced arterial partial pressure of carbon dioxide when compared to a jet nebulizer, indicating superior therapeutic efficacy.
Subject
Pediatrics, Perinatology and Child Health
Reference40 articles.
1. Clinical phenotypes and management concepts for severe, established bronchopulmonary dysplasia;Logan;Paediatr Respir Rev,2019
2. Tracheobronchomalacia is associated with increased morbidity in bronchopulmonary dysplasia;Hysinger;Ann Am Thorac Soc,2017
3. Oxidative stress and bronchopulmonary dysplasia: evidences from microbiomics, metabolomics, and proteomics;Capasso;Front Pediatr,2019
4. Comparisons and limitations of current definitions of bronchopulmonary dysplasia for the prematurity and respiratory outcomes program;Poindexter;Ann Am Thorac Soc,2015
5. Respiratory phenotypes for preterm infants, children, and adults: bronchopulmonary dysplasia and more;Collaco;Ann Am Thorac Soc,2018